Heatwurx (PCSA) News Today $0.21 0.00 (-0.61%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$0.20 -0.01 (-3.59%) As of 08/28/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock PCSA Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Heatwurx (NASDAQ:PCSA) Rating Lowered to "Hold" at Zacks Research45 minutes ago | americanbankingnews.comProcessa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury StrategiesAugust 7, 2025 | globenewswire.comProcessa Pharmaceuticals Provides Portfolio and Business UpdateJuly 1, 2025 | globenewswire.comProcessa Pares Gains on Equity Offer NewsJune 17, 2025 | marketwatch.comProcessa Pharmaceuticals Announces Pricing of $7 Million Public OfferingJune 17, 2025 | globenewswire.comProcessa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug CandidateJune 17, 2025 | globenewswire.comProcessa Pharmaceuticals to Showcase Next Generation Cancer Therapies at 2025 BIO International ConventionJune 15, 2025 | nasdaq.comProcessa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025June 13, 2025 | globenewswire.comProcessa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual MeetingMay 30, 2025 | globenewswire.comProcessa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025April 15, 2025 | markets.businessinsider.comProcessa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025April 15, 2025 | globenewswire.comProcessa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor ConferenceMarch 18, 2025 | globenewswire.comProcessa Pharmaceuticals, Inc. (PCSA): Among the Cheapest Stocks Insiders Are Buying RecentlyFebruary 21, 2025 | insidermonkey.comProcessa Pharmaceuticals faces Nasdaq delisting risk over share priceFebruary 10, 2025 | msn.comFavourable Signals For Processa Pharmaceuticals: Numerous Insiders Acquired StockFebruary 7, 2025 | finance.yahoo.comProcessa Pharmaceuticals to Present at the 2025 BIO CEO & Investor ConferenceFebruary 7, 2025 | globenewswire.comProcessa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq RulesJanuary 30, 2025 | globenewswire.comProcessa Pharmaceuticals director David Young buys $99,288 in stockJanuary 30, 2025 | msn.comProcessa Pharmaceuticals' chief business officer buys $34,691 in stockJanuary 30, 2025 | msn.comInsider Buying: Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) CEO Acquires 87,200 Shares of StockJanuary 30, 2025 | insidertrades.comProcessa Pharmaceuticals prices $5M at-the-market offeringJanuary 29, 2025 | markets.businessinsider.comProcessa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq RulesJanuary 27, 2025 | globenewswire.comProcessa Pharmaceuticals stock hits 52-week low at $0.65January 27, 2025 | msn.comProcessa Pharmaceuticals stock hits 52-week low at $0.8January 17, 2025 | msn.comProcessa Pharmaceuticals files to sell common stock, no amount givenDecember 20, 2024 | markets.businessinsider.comProcessa Pharmaceuticals files to sell common stock, no amount givenDecember 20, 2024 | markets.businessinsider.comProcessa Pharmaceuticals, Inc. (PCSA)November 21, 2024 | finance.yahoo.comProcessa Pharmaceuticals Reports Q3 2024 Financial ResultsNovember 2, 2024 | markets.businessinsider.comProcessa Pharmaceuticals Reports Third Quarter Business Highlights and Financial ResultsOctober 30, 2024 | markets.businessinsider.comBiotech Advances Gain Momentum Amid October’s Rising Breast Cancer Rates and Awareness EffortsOctober 15, 2024 | theglobeandmail.comProcessa Pharmaceuticals maintains Buy rating from H.C. WainwrightOctober 5, 2024 | uk.investing.comBuy Rating Affirmed for Processa Pharmaceuticals Amidst Promising Phase 2 Trial for NGC-CapOctober 4, 2024 | markets.businessinsider.comProcessa Pharma (NASDAQ:PCSA) Stock, Short Interest ReportOctober 3, 2024 | benzinga.comProcessa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast CancerOctober 2, 2024 | globenewswire.comInvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Participate at the H.C. Wainwright 26th Annual Global Investment Conference, ESMO Congress 2024September 3, 2024 | msn.comProcessa Pharmaceuticals to Participate in Investor and Industry Conferences During SeptemberSeptember 3, 2024 | globenewswire.comProcessa Pharmaceuticals Provides Product Pipeline and Financial UpdateAugust 28, 2024 | markets.businessinsider.comProcessa Pharmaceuticals Announces Positive Preclinical Data for NGC-IriAugust 19, 2024 | stockhouse.comAnalysts Are Bullish on Top Healthcare Stocks: Processa Pharmaceuticals (PCSA), Healthequity (HQY)August 19, 2024 | markets.businessinsider.comBioMedNewsBreaks — Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Positive Data from Two Preclinical Studies of NGC-IriAugust 19, 2024 | msn.com3 Penny Stocks to Watch Now, 8/1/24August 2, 2024 | msn.comBuy Recommendation Reaffirmed on Processa Pharmaceuticals Following IND Clearance and Executive AppointmentJuly 31, 2024 | markets.businessinsider.comProcessa Pharmaceuticals Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NGC-Cap in Breast CancerJuly 30, 2024 | finance.yahoo.comFDA approves Processa Phase 2 study for NGC-Cap, stock rallies 46%July 30, 2024 | msn.comWhy Is Processa Pharmaceuticals (PCSA) Stock Up 29% Today?July 30, 2024 | investorplace.comProcessa Pharmaceuticals Names Russell Skibsted CFO - Quick FactsJuly 19, 2024 | markets.businessinsider.comProcessa Pharmaceuticals appoints CFOJuly 19, 2024 | msn.comProcessa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal CancerJune 11, 2024 | globenewswire.comProcessa Pharmaceuticals to Participate in the EF Hutton Annual Global ConferenceMay 6, 2024 | globenewswire.comProcessa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical ResearchApril 30, 2024 | globenewswire.com Get Heatwurx News Delivered to You Automatically Sign up to receive the latest news and ratings for PCSA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PCSA Media Mentions By Week PCSA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PCSA News Sentiment▼-0.061.03▲Average Medical News Sentiment PCSA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PCSA Articles This Week▼20▲PCSA Articles Average Week Get the Latest News and Ratings for PCSA and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Heatwurx and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Enlivex Therapeutics News Sol-Gel Technologies News 180 Life Sciences News Acrivon Therapeutics News Generation Bio News PepGen News Exicure News Eagle Pharmaceuticals News Renovaro News Hyperion DeFi News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PCSA) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heatwurx Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heatwurx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access